Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
2,152 results
  • LSD1: biologic roles and therapeutic targeting. [Journal Article]
  • EEpigenomics 2016; 8(8):1103-16
  • Maiques-Diaz A, Somervaille TC
  • LSD1 (KDM1A; BHC110; AOF2) was the first protein reported to exhibit histone demethylase activity and has since been shown to have multiple essential roles in mammalian biology. Given its enzymatic a...
  • Inhibitors of LSD1 as a potential therapy for acute myeloid leukemia. [Journal Article]
  • EOExpert Opin Investig Drugs 2016; 25(7):771-80
  • Przespolewski A, Wang ES
  • CONCLUSIONS: LSD1 inhibitors represent a promising novel epigenetic approach for AML therapy. Preclinical studies have revealed that pharmacologic LD1 inhibitors function primarily by altering stem cell programs and restoring myeloid differentiation to AML cells. These effects are markedly enhanced in combination with trans-retinoic acid or histone deacetylase inhibitors with little toxicity. Currently, multiple oral LSD1 inhibitors are undergoing phase 1 investigation in patients with AML. The results of these clinical trials are eagerly awaited.
New Search Next